Get the Stockscreener App
0.07
19.63%
-0.0171
Bio Path Holdings Inc stock is traded at $0.07, with a volume of 27,657.
It is down -19.63% in the last 24 hours and down -19.63% over the past month.
See More
Previous Close:
$0.0871
Open:
$0.0751
24h Volume:
27,657
Relative Volume:
27.32
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-16.08M
P/E Ratio:
-0.00203
EPS:
-34.43
Net Cash Flow:
$-11.54M
1W Performance:
-19.63%
1M Performance:
-19.63%
6M Performance:
-86.27%
1Y Performance:
-97.18%
1-Day Range:
$0.07
$0.0759
1-Week Range:
$0.07
$0.0759
52-Week Range:
$0.07
$0.12
Bio Path Holdings Inc Stock (BPTH) Company Profile
Compare BPTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BPTH
Bio Path Holdings Inc
|
0.07 | 0 | 0 | -16.08M | -11.54M | -34.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
451.79 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.71 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
843.89 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.66 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
198.78 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bio Path Holdings Inc Stock (BPTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-11-21 | Initiated | ROTH Capital | Buy |
| Nov-13-17 | Reiterated | H.C. Wainwright | Buy |
| Aug-10-16 | Reiterated | Maxim Group | Buy |
| Apr-18-16 | Initiated | Rodman & Renshaw | Buy |
| Jun-02-14 | Resumed | Maxim Group | Buy |
| May-09-14 | Initiated | Maxim Group | Buy |
View All
Bio Path Holdings Inc Stock (BPTH) Latest News
North American Morning Briefing : Dow Futures Climb, Nasdaq Futures Fall -2- - marketscreener.com
Marginal Zone Lymphoma Treatment Pipeline Shows Strong Momentum as 50+ Pharma Companies in the Race | DelveInsight - The Globe and Mail
Reviewing Eagle Pharmaceuticals (NASDAQ:EGRX) and Bio-Path (NASDAQ:BPTH) - Defense World
P 500 performance this yearInflation Watch & Technical Pattern Alert System - Newser
Can Bio Path Holdings Inc. (IBP0) stock retain market dominanceJuly 2025 Technicals & Real-Time Volume Triggers - Newser
Acute Myeloid Leukemia Clinical Trial Pipeline Appears - GlobeNewswire
What consensus target says about Bio Path Holdings Inc. (IBP0) stockJuly 2025 Sector Moves & Daily Entry Point Trade Alerts - Newser
Analyzing Aadi Bioscience (NASDAQ:AADI) & Bio-Path (NASDAQ:BPTH) - Defense World
Bio-Path reports positive trial outcomes for cancer treatments - MSN
RNA Interference Pipeline Insights Report 2025: DelveInsight Highlights Emerging Therapeutics Transforming the Future Treatment Landscape - Barchart.com
Axos Financial loses $15M indemnification fight after merger trading fiasco - InvestmentNews
Bio-Path Holdings Inc. (BPTH) Stock Price | Live Quotes & Charts | PINL - StocksToTrade
MSN Money - MSN
North American Morning Briefing : Stock Futures Mostly Lower, AI Volatility Persists -2- - MarketScreener
Bio-Path Holdings Delays 10-Q Filing - MSN
Why ETFs are accumulating Bio Path Holdings Inc. (IBP0) stockTrade Volume Summary & Safe Entry Zone Tips - newser.com
Will Bio Path Holdings Inc. (IBP0) stock benefit from infrastructure billJuly 2025 PreEarnings & Long-Term Capital Growth Strategies - newser.com
Is Bio Path Holdings Inc. (IBP0) stock a fit for income portfoliosTrade Performance Summary & AI Enhanced Trading Alerts - newser.com
Will Bio Path Holdings Inc. (IBP0) stock rise with strong economyRisk Management & Long Hold Capital Preservation Tips - newser.com
Bio-Path Holdings announces board resignation and outlines turnaround plans - Investing.com Nigeria
Small Interfering RNA (siRNA) Therapeutics Market Future Trends and Scope Analysis Report - openPR.com
North American Morning Briefing : Futures Fall as Sentiment Weighed by Uncertainties -2- - MarketScreener
Will Bio Path Holdings Inc. (IBP0) stock outperform benchmarksRate Cut & Free Fast Gain Swing Trade Alerts - newser.com
Bio Path Holdings Inc Stock (BPTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.56%
1.23%
Cap:
|
Volume (24h):